Roche ’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news